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The anti-inflammatory effects of IVIg have been adoptively transferred using IVIg-primed cells in autoimmunity and inflammatory states (reviewed in Crow et al 1 and Lazarus 2 ). Although dendritic cells (DCs) have entered the spotlight in this process, the downstream target of these cells has been unknown. In this issue of Blood, Huang and colleagues observe that IVIg-primed DCs can surprisingly induce downstream regulatory effects in murine ITP at the level of the platelet rather than the phagocyte. 3 I ntravenous immunoglobulin (IVIg) has beneficial effects in a wide array of inflammatory states and autoimmune diseases. Although much remains to be unveiled about all of the details surrounding the mechanistic effects of IVIg, it has been proposed that activating Fc␥ receptors on the surface of DCs are a primary target of IVIg. 4 A specific role for Fc␥RIII-dependent signaling has also been implicated in IVIG action in murine immune thrombocytopenia (ITP). 5 What has been missing is an understanding of the downstream pathway whereby these IVIg-primed DCs mediate their inhibitory effects. Although the downstream mechanistic pathway induced by DCs is likely complex, the general assumption was that platelets were only the victims in ITP and that the target of this immune regulation would more logically affect the macrophage. In sharp contrast to this "default" thinking, Huang and coworkers now demonstrate that IVIG-primed DCs mediate an anti-inflammatory activity at the level of the platelet itself rather than an effect on the phagocytic cell in a murine model of ITP (see figure) .
DCs purified from the spleens of naive mice were incubated in vitro with IVIg and adoptively transferred into recipient ITP mice, similar to a previous study. 4 After 24 hours, the degree of thrombocytopenia was assessed in the recipient mice, the spleen removed, and a binding interaction assay performed with CD14 ϩ monocyte/macrophages (M) and opsonized platelets from selected groups of mice. The authors assessed the ability of M from IVIg-DC-primed mice versus M from naive mice to engage opsonized platelets from IVIg-DC-primed mice versus those from naive mice. This novel approach allowed the authors to map whether the downstream effects of IVIg-DC priming orchestrate a change in the attributes of the phagocytic M versus the platelet. Surprisingly, only under conditions where the platelets were isolated from mice treated with IVIg-primed DCs did the number of interactions between the opsonized platelets and M decrease. This is the first clear indication that IVIg targets (or marks) the platelets rather than phagocytic cells.
Although details on how the platelets are marked or affected by this IVIg pathway remain to be solved, IVIg appeared to have an absolute requirement for P-selectin in the recipient mice. 3 P-selectin or P-selectin glycoprotein ligand-1 (PSGL-1) expression by platelets, DCs, or other cells involved in IVIg action (such as endothelial cells 6 ) could interact together to either further complicate these IVIg-directed nuptials or help provide clues as to how or why IVIg works in the myriad of diseases where it is beneficial.
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In this issue of Blood, Barker et al demonstrate that third-party non-neonatal T cells specific for Epstein-Barr virus (EBV) can be safely used to treat EBVassociated disease after allogeneic umbilical cord blood (UCB) transplantation (UCBT). 1 This is made possible by the a priori generation of cryopreserved banks of EBV-specific T cells from peripheral blood.
T he clinical benefits of infusing third-party T cells is predicted from extensive nonhuman and human experiences demonstrating that the adoptive transfer of antigen-specific T cells from a donor can successfully augment an immune response protecting and treating a designated recipient against pathogens and tumors after allogeneic hematopoietic stem cell transplantation (HSCT). What is only recently becoming apparent is that one donor can be used to generate antigen-specific T cells that can be infused into multiple recipients.
The report in this issue joins a growing list of clinical trials in which previously generated cryopreserved third-party EBV-specific T cells have been adoptively transferred. [2] [3] [4] Multiple infusions were administered to achieve a clinical response with thawed T cells given every week, every 2 weeks, or every 3 weeks, at intravenous doses of 10 6 /kg/infusion to 2 ϫ 10 6 /kg/infusion based on recipient weight. These data describe clinical responses to opportunistic EBV infection and associated disease that were apparently longlasting and significantly were not associated with severe adverse effects. The anonymity, small size, and functional naiveté of the UCB graft typically preclude isolation of clinicalgrade T cells with desired specificity and suitable for adoptive immunotherapy. Thus, the testing of third-party EBV-specific T cells from non-neonatal donors is particularly compelling in this clinical context. In aggregate, Barker's data highlight that third-party 
